Advancements in pancreatic neuroendocrine tumors

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 5, 2013, Pages 477-490

  Sadaria, Miral R ^a   Hruban, Ralph H ^b   Edil, Barish H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

endocrine tumor; everolimus; islet cell tumor; liver metastases; pancreatectomy; pancreatic neuroendocrine tumor; sunitinib; targeted therapy

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CHLOROZOTOCIN; CYTOTOXIC AGENT; DACARBAZINE; DALOTUZUMAB; DIAZOXIDE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; INTERFERON; LUTETIUM 177; OCTREOTIDE; PAZOPANIB; PLACEBO; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TUMOR MARKER; YTTRIUM 90;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOID; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG RESPONSE; ENDOSCOPIC ECHOGRAPHY; FATIGUE; FLU LIKE SYNDROME; HUMAN; INSULINOMA; INTERMETHOD COMPARISON; LABORATORY TEST; LAPAROSCOPIC SURGERY; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LYMPH NODE METASTASIS; MEDICAL HISTORY; MINIMALLY INVASIVE SURGERY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYOSITIS; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS FISTULA; PANCREAS RESECTION; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PATIENT SAFETY; POLYNEUROPATHY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIDE EFFECT; SPLENECTOMY; STOMACH EMPTYING; STOMACH FUNCTION DISORDER; SYMPTOM ASSESSMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR ABLATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84883213227     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2013.811058     Document Type: Review

References (98)

1. Yao JC, Eisner MP, Leary C et al. Population-based study of islet cell carcinoma. Ann. Surg. Oncol. 14(12), 3492-3500 (2007).
2. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28(1), 69-76 (2010).
3. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5), 1469-1492 (2008).
4. Oberg K. Pancreatic endocrine tumors. Semin. Oncol. 37(6), 594-618 (2010).
5. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40(1), 1-18, vii (2011).
6. Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch. A. Pathol. Anat. Histol. 365(4), 275-288 (1975).
7. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig. Dis. Sci. 36(7), 933-942 (1991).
8. Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr. Treat. Options Oncol. 13(1), 24-34 (2012).
9. Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr. Res. 36(1), 35-43 (2011).
10. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19(10), 1727-1733 (2008).
11. de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat. Rev. Gastroenterol. Hepatol. 9(4), 199-208 (2012).
12. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063-3072 (2008).
13. Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J. Gastrointest. Oncol. 3(3), 182-188 (2012).
14. Zhou C, Zhang J, Zheng Y, Zhu Z. Pancreatic neuroendocrine tumors: a comprehensive review. Int. J. Cancer 131(5), 1013-1022 (2012).
15. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat. Rev. Endocrinol. 8(1), 54-64 (2012).
16. Remes SM, Tuominen VJ, Helin H, Isola J, Arola J. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am. J. Surg. Pathol. 36(9), 1359-1363 (2012).
17. Strosberg JR, Cheema A, Weber JM et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann. Surg. 256(2), 321-325 (2012).
18. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur. J. Surg. Oncol. 34(3), 324-332 (2008).
19. Li J, Luo G, Fu D et al. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med. Oncol. 28(4), 1027-1031 (2011).
20. Nissen NN, Kim AS, Yu R et al. Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am. Surg. 75(10), 1025-1029 (2009).
21. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr. Opin. Oncol. 24(1), 46-55 (2012).
22. Kulke MH, Benson AB 3rd, Bergsland E et al.; National Comprehensive Cancer Networks. Neuroendocrine tumors. J. Natl Compr. Canc. Netw. 10(6), 724-764 (2012).
23. Anlauf M, Perren A, Klöppel G. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 74(5), 279-284 (2007).
24. Garbrecht N, Anlauf M, Schmitt A et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr. Relat. Cancer 15(1), 229-241 (2008).
25. Davies K, Conlon KC. Neuroendocrine tumors of the pancreas. Curr. Gastroenterol. Rep. 11(2), 119-127 (2009).
26. Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg. Clin. North Am. 89(1), 249-266, x (2009).
27. Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev. Gastroenterol. Hepatol. 6(3), 313-334 (2012).
28. Vinik AI, Silva MP, Woltering EA et al. Biochemical testing for neuroendocrine tumors. Pancreas 38(8), 876-889 (2009).
29. Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao. Paulo) 67 (Suppl. 1), 109-112 (2012).
30. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 18 (Suppl. 1), S17-S25 (2011).
31. Coakley FV, Hanley-Knutson K, Mongan J, Barajas R, Bucknor M, Qayyum A. Pancreatic imaging mimics: part 1, imaging mimics of pancreatic adenocarcinoma. AJR Am. J. Roentgenol. 199(2), 301-308 (2012).
32. Raman SP, Hruban RH, Cameron JL, Wolfgang CL, Fishman EK. Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. AJR Am. J. Roentgenol. 199(2), 309-318 (2012).
33. Galvin A, Sutherland T, Little AF. Part 1: CT characterisation of pancreatic neoplasms: a pictorial essay. Insights Imaging 2(4), 379-388 (2011).
34. Pais SA, Al-Haddad M, Mohamadnejad M et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest. Endosc. 71(7), 1185-1193 (2010).
35. Ellison TA, Edil BH. The current management of pancreatic neuroendocrine tumors. Adv. Surg. 46, 283-296 (2012).
36. Joseph S, Wang YZ, Boudreaux JP et al. Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol. Metab. Clin. North Am. 40(1), 205-231, x (2011).
37. Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J. Gastroenterol. 47(9), 941-960 (2012).
38. Frilling A, Akerström G, Falconi M et al. Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat. Cancer 19(5), R163-R185 (2012).
39. Sundin A. Imaging of neuroendocrine tumors. Expert Opin. Med. Diagn. 6(5), 473-483 (2012).
40. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6), 361-379 (2010).
41. Frilling A, Sotiropoulos GC, Radtke A et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann. Surg. 252(5), 850-856 (2010).
42. Kim MK. Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors. Gut Liver 6(4), 405-410 (2012).
43. Atiq M, Bhutani MS, Bektas M et al. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig. Dis. Sci. 57(3), 791-800 (2012).
44. Lennon AM, Newman N, Makary MA et al. EUS-guided tattooing before laparoscopic distal pancreatic resection (with video). Gastrointest. Endosc. 72(5), 1089-1094 (2010).
45. Cauley CE, Pitt HA, Ziegler KM et al. Pancreatic enucleation: improved outcomes compared to resection. J. Gastrointest. Surg. 16(7), 1347-1353 (2012).
46. Pitt SC, Pitt HA, Baker MS et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate J. Gastrointest. Surg. 13(9), 1692-1698 (2009).
47. Bilimoria KY, Tomlinson JS, Merkow RP et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J. Gastrointest. Surg. 11(11), 1460-1467; discussion 1467 (2007).
48. Casadei R, Ricci C, Rega D et al. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate A single-center experience. Pancreas 39(6), 825-828 (2010).
49. Inchauste SM, Lanier BJ, Libutti SK et al. Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. World J. Surg. 36(7), 1517-1526 (2012).
50. Cherif R, Gaujoux S, Couvelard A et al. Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J. Gastrointest. Surg. 16(11), 2045-2055 (2012).
51. Falconi M, Zerbi A, Crippa S et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann. Surg. Oncol. 17(6), 1621-1627 (2010).
52. Lavu H, Knuth JL, Baker MS et al. Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon's clinical practice. HPB (Oxford) 10(6), 491-497 (2008).
53. Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch. Surg. 137(2), 164-168 (2002).
54. Casadei R, Monari F, Buscemi S et al. Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. Updates Surg. 62(1), 41-46 (2010).
55. Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J. Gastroenterol. 16(36), 4519-4525 (2010).
56. Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J. Gastrointest. Surg. 11(2), 209-216 (2007).
57. Crippa S, Boninsegna L, Partelli S, Falconi M. Parenchyma-sparing resections for pancreatic neoplasms. J. Hepatobiliary Pancreat. Sci. 17(6), 782-787 (2010).
58. Kooby DA, Chu CK. Laparoscopic management of pancreatic malignancies. Surg. Clin. North Am. 90(2), 427-446 (2010).
59. Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-Analysis. Ann. Surg. 255(6), 1048-1059 (2012).
60. Newman NA, Lennon AM, Edil BH et al. Preoperative endoscopic tattooing of pancreatic body and tail lesions decreases operative time for laparoscopic distal pancreatectomy. Surgery 148(2), 371-377 (2010).
61. Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the Accordion Severity Grading System. J. Am. Coll. Surg. 215(6), 810-819 (2012).
62. Lee LC, Grant CS, Salomao DR et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 152(6), 965-974 (2012).
63. Bettini R, Partelli S, Boninsegna L et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150(1), 75-82 (2011).
64. Doherty GA, Bai A, Hanidziar D et al. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur. J. Immunol. 42(11), 3062-3072 (2012).
65. Niina Y, Fujimori N, Nakamura T et al. The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 6(3), 287-294 (2012).
66. Gaujoux S, Gonen M, Tang L et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann. Surg. Oncol. 19(13), 4270-4277 (2012).
67. Cusati D, Zhang L, Harmsen WS et al. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J. Am. Coll. Surg. 215(1), 117-124; discussion 124 (2012).
68. Kulke MH, Anthony LB, Bushnell DL et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6), 735-752 (2010).
69. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J. Gastrointest. Surg. 14(3), 541-548 (2010).
70. Watzka FM, Laumen C, Fottner C et al. Resection strategies for neuroendocrine pancreatic neoplasms. Langenbecks. Arch. Surg. 398(3), 431-440 (2013).
71. De Jong MC, Farnell MB, Sclabas G et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann. Surg. 252(1), 142-148 (2010).
72. Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg. Today 41(10), 1332-1343 (2011).
73. Chan G, Kocha W, Reid R, Taqi A, Wall W, Quan D. Liver transplantation for symptomatic liver metastases of neuroendocrine tumours. Curr. Oncol. 19(4), 217-221 (2012).
74. Alistar A, Sung M, Kim M, Holcombe RF. Clinical pathways for pancreatic neuroendocrine tumors. J. Gastrointest. Cancer 43(4), 532-540 (2012).
75. Reddy SK, Clary BM. Neuroendocrine liver metastases. Surg. Clin. North Am. 90(4), 853-861 (2010).
76. Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different Curr. Oncol. Rep. 14(3), 249-256 (2012).
77. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies Curr. Opin. Oncol. 22(4), 381-386 (2010).
78. Rinke A, Müller HH, Schade-Brittinger C et al.; PROMID Study Group. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656-4663 (2009).
79. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26(13), 2124-2130 (2008).
80. Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29(17), 2416-2423 (2011).
81. Sowa-Staszczak A, Pach D, Chrzan R et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur. J. Nucl. Med. Mol. Imaging 38(9), 1669-1674 (2011).
82. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am. J. Gastroenterol. 103(2), 475-483; quiz 484 (2008).
83. Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat. Rev. 37(2), 127-132 (2011).
84. Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-enteropancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 23(Suppl. 7), vii 124-130 (2012).
85. Eriksson B, Annibale B, Bajetta E et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2), 214-219 (2009).
86. Oberstein PE, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors. JOP 13(4), 372-375 (2012).
87. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326(8), 519-523 (1992).
88. Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 22(23), 4762-4771 (2004).
89. Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2), 268-275 (2011).
90. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199-1203 (2011).
91. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr. Treat. Options Oncol. 12(2), 136-148 (2011).
92. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediategrade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol. 26(26), 4311-4318 (2008).
93. Yao JC, Shah MH, Ito T et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514-523 (2011).
94. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501-513 (2011).
95. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26(20), 3403-3410 (2008).
96. Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother. Pharmacol. 71(5), 1241-1246 (2013).
97. Phan AT, Oberg K, Choi J et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: welldifferentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 39(6), 784-798 (2010).
98. Reidy-Lagunes DL, Vakiani E, Segal MF et al. A Phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118(19), 4795-4800 (2012).